Company intelligence / Profile preview

TME Therapeutics

San Diego, California, United States

Ownership: Private
Development stage: Other

Overview

TME Therapeutics is a biotechnology company focused on developing novel cancer therapies that target the tumor microenvironment (TME). The company's lead research centers on the role of Neuropilin-1 (NRP1) in modulating immune responses and vascularization within tumors. By developing antibodies that specifically inhibit NRP1's interaction with its ligands, TME Therapeutics aims to overcome immune suppression and enhance the efficacy of existing immunotherapies. The company is currently in the pre-clinical stage, advancing its pipeline toward IND-enabling studies for the treatment of various solid tumors.

Therapeutic areas: Oncology
Modalities: Monoclonal antibodyAntibody
Industry: Biotech

Drug pipeline

6 assets

GALNAC4S-6ST siRNA-2

Preclinical

5 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on TME Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TME Therapeutics.

Explore the full profile